+ Watch ITMN
on My Watchlist
The Company is a biotech company focused on developing and commercializing innovative therapies in pulmonology and hepatology.
I suppose I could do a discounted cash flow analysis for Intermune, factoring in the probabilities of different reimbursement levels for pirfenidone in the US and potential competition from nintedanib if Boehringer reports positive data from the INPULSIS trials in May. Then again, I could just wing it and spend that time playing on the Ipad with my daughter instead. No contest, really. Based on the way I've seen this stock behave over the last seven years, I see the share price reaching at least 36 some time before the ATS conference in mid-May. My level of confidence isn't enough to get me to buy in at a share price of 33 for a potential 10% gain, but if the stock were to decline below 30 and stabilize I would likely make Intermune a small part of the zzporte portfolio.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions